Search

Search Results

• THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM

  May Basood, Howard S. Oster, Moshe Mittelman

  e2018046

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.046

  2952

  PDF: 1328

  HTML: 494

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4046

  PDF: 1414

  HTML: 569

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1278

  HTML: 360

  PDF: 785

• IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

  Rosangela Invernizzi, Federica Quaglia, Matteo Giovanni Della Porta

  e2015035

  2015-04-26

  https://doi.org/10.4084/mjhid.2015.035

  3192

  PDF: 2215

  HTML: 23284

  Untitled: 183

  Untitled: 186

  Untitled: 208

• DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.

  Matteo Della Porta, Cristina Picone

  e2017017

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.017

  4629

  PDF: 1729

  HTML: 2094

• A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY

  Flavia Mayer, Laura Faglioni, Nera Agabiti, Susanna Fenu, Francesco Buccisano, Roberto Latagliata, Roberto Ricci, Maria Antonietta Aloe Spiriti, Caterina Tatarelli, Massimo Breccia, Giuseppe Cimino, Luana Fianchi, Svitlana Gumenyuk, Stefano Mancini, Luca Maurillo, Carolina Nobile, Pasquale Niscola, Anna Lina Piccioni, Agostino Tafuri, Giulio Trapè, Alessandro Andriani, Paolo De Fabritis, Maria Teresa Voso, Marina Davoli, Gina Zini

  e2017046

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.046

  2537

  PDF: 949

  HTML: 1092

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  1858

  PDF: 702

  HTML: 677

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  1962

  PDF: 1576

  HTML: 344

• MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY

  Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

  e2017021

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.021

  3298

  PDF: 1250

  HTML: 1845

  Fig.1: 178

  Fig. 2: 186

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3609

  PDF: 1596

  HTML: 11456

  Figures Haase: 172

• REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE

  Emmanuel Gyan, François Dreyfus, Pierre Fenaux

  e2015018

  2015-02-13

  https://doi.org/10.4084/mjhid.2015.018

  12221

  PDF: 1624

  HTML: 4138

  Cover letter: 177

  Figure 1: 171

• ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

  Teresa L Field, Claudio Anasetti

  e2010019

  2010-07-19

  https://doi.org/10.4084/mjhid.2010.019

  1255

  PDF: 564

  HTML: 1172

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  1924

  PDF: 731

  HTML: 3098

• CLINICO-PATHOLOGICAL SPECTRUM AND NOVEL KARYOTYPIC FINDINGS IN MYELODYSPLASTIC SYNDROME: EXPERIENCE OF TERTIARY CARE CENTRE IN INDIA.

  Ruchi Gupta, Khaliqur Rahman, Manish Kumar Singh, Surabhi Kumari, Geeta yadav, Soniya Nityanand

  e2017048

  2017-08-16

  https://doi.org/10.4084/mjhid.2017.048

  1900

  PDF: 745

  HTML: 929

  Untitled: 185

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2720

  PDF: 972

  HTML: 5494

• RECENT ADVANCES IN THE 5Q- SYNDROME

  Andrea Pellagatti, Jacqueline Boultwood

  e2015037

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.037

  2664

  PDF: 1732

  HTML: 3624

  Pellagatti Fig 1: 182

  Pellagatti Fig. 2: 182

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.

  Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

  e2018005

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.005

  4074

  PDF: 1011

  HTML: 1147

• ASSOCIATION BETWEEN LEUKEMIC EVOLUTION AND UNCOMMON CHROMOSOMAL ALTERATIONS IN PEDIATRIC MYELODYSPLASTIC SYNDROME

  Viviane Lamim Lovatel, Beatriz Ferreira da Silva , Eliane Ferreira Rodrigues , Maria Luiza Rocha da Rosa Borges , Rita de Cássia Barbosa Tavares, Ana Paula Silva Bueno, Elaine Sobral da Costa, Terezinha de Jesus Marques , Teresa de Souza Fernandez

  e2024003

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.003

  1117

  PDF: 1327

  HTML: 111

• A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

  Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani

  e2012017

  2012-03-13

  https://doi.org/10.4084/mjhid.2012.017

  1099

  PDF: 639

  HTML: 726

• miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS

  Meiwan Cao, BaoLing Peng, WanFu Xu, PeiYu Chen, Huan Chen, LiPing Ye, Jing Xie, HongLi Wang, Lu Ren, LiYa Xiong, JingNan Zhu, XiangYe Xu, LanLan Geng, SiTang Gong

  e2023040

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.040

  656

  PDF: 782

  PDF Supp. Files: 68

  HTML: 169

• BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN

  Maria Teresa Voso, Giulia Falconi, Dr. Fabiani

  e2023055

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.055

  1668

  PDF: 921

  HTML: 126

• PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY

  Alfredo Molteni, Emanuele Ravano, Marta Riva, Michele Nichelatti, Laura Bandiera, Lara Crucitti, Mauro Truini, Roberto Cairoli

  e2019015

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.015

  1748

  PDF: 947

  HTML: 286

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4189

  PDF: 1686

  HTML: 1094

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  1823

  PDF: 813

  HTML: 1222

• Anemia in the elderly: not always what it seems.

  Marco Cerrano, Elena Crisà, Valentina Giai, Mario Boccadoro, Dario Ferrero

  e2016017

  2016-02-25

  https://doi.org/10.4084/mjhid.2016.017

  3223

  PDF: 984

  HTML: 1749

  Figure 1: 156

  Figure 1 revised: 159

• PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome

  Kalman Filanovsky, Michal Haran, Vita Mirkin, Andrei Braester, Olga Shevetz, Anfisa Stanevsky, Erica Sigler, Ekaterina Votinov, Yehudit Zalzman-Amir, Alain Berrebi, Atan Gross, Lev Shvidel

  e2020072

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.072

  993

  PDF: 728

  HTML: 265

• GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE

  Francesco Fabozzi, Angela Mastronuzzi

  e2023032

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.032

  1812

  PDF: 470

  HTML: 492

• ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children

  Ilaria Lazzareschi, Elena Rossi, Antonietta Curatola, Giovanna Capozio, Luca Benacquista, Ludovica Iezzi, Donato Rigante

  e2022008

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.008

  1846

  PDF: 1040

  HTML: 552

• DECREASED CD10 EXPRESSION IN THE BONE MARROW NEUTROPHILS OF HIV POSITIVE PATIENTS

  Annemarie Van de Vyver, Adele Visser

  e2010032

  2010-11-10

  https://doi.org/10.4084/mjhid.2010.032

  1177

  PDF: 830

  HTML: 1092

  Coverletter: 172

• PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM

  Richard A. Larson, Michelle Le Beau

  e2011032

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.032

  2720

  PDF: 869

  HTML: 1848

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1219

  PDF: 764

  HTML: 110

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2052

  PDF: 695

  HTML: 1609

• 5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

  Mariangela Greco, Marianna Criscuolo, Luana Fianchi, Livio Pagano, Maria Teresa Voso

  e2011011

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.011

  1522

  PDF: 736

  HTML: 1095

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1040

  PDF: 814

  HTML: 218

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2031

  PDF: 1116

  HTML: 1964

• Seven-Year Course of Hypoplastic Myelodysplastic Syndrome Unmasked by Secondary and Neurosyphilis.

  Ali Turunç, Hüseyin Derya Dinçyürek, Birol Güvenç

  e2026026

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.026

  395

  PDF: 213

  HTML: 71

• Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation Inflammatory marker elevation in MDS

  Howard Oster, Ekaterina Sklyar, Noa Golsdshmidt, Moshe Mittelman

  e2023044

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.044

  799

  PDF: 615

  HTML: 186

• ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS

  Lourdes Vazquez

  e2016040

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.040

  4180

  PDF: 1331

  HTML: 2022

• Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy

  Antonella Vaccarino, Irene Dogliotti, Fabio Marletto, Andrea Demarchi, Mario Bazzan

  e2016050

  2016-10-20

  https://doi.org/10.4084/mjhid.2016.050

  2702

  PDF: 719

  HTML: 1240

  Blood Count trend before and during lenalidomide treatment: 149

  Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 166

• THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies

  Emine Atli, Rasime Kalkan, Cisem Mail, Damla Eker, Ufuk Demirci, Selma Demir, Sinem Yalcintepe, Hakki Onur Kirkizlar, Engin Atli, Hakan Gurkan, Ahmet Muzaffer Demir

  e2021013

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.013

  1411

  PDF: 497

  HTML: 236

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1001

  PDF: 667

  HTML: 330

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2188

  PDF: 732

  HTML: 774

• ACTIVIN RECEPTOR LIGAND FOR THR TREATMENT OF BETA-THALASSEMIA: a SERENDIPITOUS DISCOVERY

  Irene Motta, Valentina Brancaleoni, Isabella Nava, Paola Delbini, Lorena Duca

  e2020075

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.075

  1422

  PDF: 1348

  HTML: 463

• THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA

  Dennis A Eichenauer, Andreas Engert

  e2011046

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.046

  2205

  PDF: 705

  HTML: 1170

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2390

  PDF: 754

  HTML: 1719

• Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in a Child with Myelodysplastic Neoplasm with Complex Karyotype and ETV6 Variant: Challenges in Treatment

  Elaiza Almeida Antônio de Kós , Viviane Lamim Lovatel , Rita de Cássia Barbosa Tavares , Gerson Moura Ferreira , Bernadete Evangelho Gomes, Ana Paula Silva Bueno, Elaine Sobral da Costa , Teresa de Souza Fernandez

  e2024040

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.040

  728

  PDF: 929

  HTML: 77

• AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.

  Pasquale Niscola

  e2014020

  2014-02-16

  https://doi.org/10.4084/mjhid.2014.020

  1594

  PDF: 857

  HTML: 2758

• INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER

  Caterina Giovanna Valentini, Luana Fianchi, Maria Teresa Voso, Morena Caira, Giuseppe Leone, Livio Pagano

  e2011069

  2011-12-22

  https://doi.org/10.4084/mjhid.2011.069

  3136

  PDF: 900

  HTML: 2923

• IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy

  İbrahim Halil Açar, Sebnem Izmir Güner , Muzeyyen Aslaner Ak, Mesut Gocer, Erman Ozturk , Figen Atalay, Gulden Sincan , Aysun Senturk Yikilmaz, Omer Ekinci, Idris Ince, Emine Gulturk , Nazli Demir, Ali Dogan, Yildiz Ipek, Birol Guvenc

  e2022074

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.074

  1340

  PDF: 707

  HTML: 189

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2240

  PDF: 910

  HTML: 355